188 related articles for article (PubMed ID: 9867152)
21. Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer.
Weiss K; Köck HH; Atefie K; Sinzinger H
Rev Esp Med Nucl; 2001 Jun; 20(4):311-2. PubMed ID: 11940421
[No Abstract] [Full Text] [Related]
22. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
23. Estimated human absorbed dose of a new (153)Sm bone seeking agent based on biodistribution data in mice: Comparison with (153)Sm-EDTMP.
Yousefnia H; Zolghadri S
Phys Med; 2015 Nov; 31(7):714-9. PubMed ID: 26095757
[TBL] [Abstract][Full Text] [Related]
24. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
Serafini AN
Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
[TBL] [Abstract][Full Text] [Related]
25. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.
Collins C; Eary JF; Donaldson G; Vernon C; Bush NE; Petersdorf S; Livingston RB; Gordon EE; Chapman CR; Appelbaum FR
J Nucl Med; 1993 Nov; 34(11):1839-44. PubMed ID: 8229221
[TBL] [Abstract][Full Text] [Related]
26. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
[TBL] [Abstract][Full Text] [Related]
27. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.
Tian JH; Zhang JM; Hou QT; Oyang QH; Wang JM; Luan ZS; Chuan L; He YJ
Eur J Nucl Med; 1999 Jan; 26(1):2-7. PubMed ID: 9933654
[TBL] [Abstract][Full Text] [Related]
28. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
Sandeman TF; Budd RS; Martin JJ
Clin Oncol (R Coll Radiol); 1992 May; 4(3):160-4. PubMed ID: 1375094
[TBL] [Abstract][Full Text] [Related]
29. [Three-dimensional dose calculation of 153Sm-EDTMP in treating bone metastasis--comparison of Monte Carlo and S value calculation methods].
Chen LX; Liu XW; Gan F; Tang Q; You RA; Zhang WG; Fan W
Ai Zheng; 2006 Nov; 25(11):1399-405. PubMed ID: 17094909
[TBL] [Abstract][Full Text] [Related]
30. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA
Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
[TBL] [Abstract][Full Text] [Related]
31. 153Sm-EDTMP for bone pain palliation in skeletal metastases.
Maini CL; Bergomi S; Romano L; Sciuto R
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S171-8. PubMed ID: 15127241
[TBL] [Abstract][Full Text] [Related]
32. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
33. [Inhibitory effect of samarium-153-labeled ethylenediaminetetramethylene phosphonate (EDTMP) on bone invasion and osteolysis in Walker 256 carcinoma bearing rats].
Shi B; Fu Z; Lei XH
Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):423-6. PubMed ID: 10920873
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model.
Louw WK; Dormehl IC; van Rensburg AJ; Hugo N; Alberts AS; Forsyth OE; Beverley G; Sweetlove MA; Marais J; Lötter MG; van Aswegen A
Nucl Med Biol; 1996 Nov; 23(8):935-40. PubMed ID: 9004281
[TBL] [Abstract][Full Text] [Related]
35. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.
Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S
J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829
[TBL] [Abstract][Full Text] [Related]
36. Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs.
Bryan JN; Bommarito D; Kim DY; Berent LM; Bryan ME; Lattimer JC; Henry CJ; Engelbrecht H; Ketring A; Cutler C
J Nucl Med Technol; 2009 Mar; 37(1):45-52. PubMed ID: 19223431
[TBL] [Abstract][Full Text] [Related]
37. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].
Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY
Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908
[TBL] [Abstract][Full Text] [Related]
38. Samarium-153 therapy for prostate cancer: the evaluation of urine activity, staff exposure and dose rate from patients.
Parlak Y; Gumuser G; Sayit E
Radiat Prot Dosimetry; 2015 Mar; 163(4):468-72. PubMed ID: 25063786
[TBL] [Abstract][Full Text] [Related]
39. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
Resche I; Chatal JF; Pecking A; Ell P; Duchesne G; Rubens R; Fogelman I; Houston S; Fauser A; Fischer M; Wilkins D
Eur J Cancer; 1997 Sep; 33(10):1583-91. PubMed ID: 9389919
[TBL] [Abstract][Full Text] [Related]
40. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography.
Rösch F; Herzog H; Plag C; Neumaier B; Braun U; Müller-Gärtner HW; Stöcklin G
Eur J Nucl Med; 1996 Aug; 23(8):958-66. PubMed ID: 8753686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
